Table 1.

Summary of pharmacological properties and basal level [³H]-D-Asp uptake

	Substrate/Inhibitor
cell line	L-Glu (μM) IC50[pIC50 ± S.E.M.]	UCPH (μM) IC50[pIC50 ± S.E.M.]	TBOA (μM) IC50[pIC50 ± S.E.M.]	Basal Uptake [% of parental]
HCT116-PAR	21 [4.67 ± 0.04]	>100 [<4.0]	1.8 [5.75 ± 0.03]	100
HCT116-SN38	21 [4.67 ± 0.01]	>100 [<4.0]	1.5 [5.83 ± 0.08]	40 ± 1.8***
HCT116-Oxa	21 [4.67 ± 0.01]	>100 [<4.0]	1.5 [5.75 ± 0.08]	73 ± 6.9*
LoVo-PAR	26 [4.59 ± 0.04]	>100 [<4.0]	1.4 [5.84 ± 0.03]	100
LoVo-SN38	28 [4.54 ± 0.10]	>100 [<4.0]	1.9 [5.83 ± 0.11]	275 ± 35**
LoVo-Oxa	23 [4.64 ± 0.06]	>100 [<4.0]	2.7 [5.75 ± 0.03]	97 ± 8.0 NS

IC₅₀ values for the three compounds are in μM, with pIC₅₀ values in brakets. The basal [³H]-D-Asp uptake data are based on the measured uptake in the chemotherapeutic-cells normalized to that in the relevant parental cell line on the experiment performed in duplicate. *) p <0.05,**) p <0.01,and ***) p <0.001, Compared to parental cell by two-tailed Student’s t-test